{"id":828906,"date":"2025-03-24T08:18:07","date_gmt":"2025-03-24T12:18:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\/"},"modified":"2025-03-24T08:18:07","modified_gmt":"2025-03-24T12:18:07","slug":"aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\/","title":{"rendered":"Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk<\/b><\/p>\n<p class=\"bwalignc\"><i>Acquisition is key to Pearsanta\u2019s mission of addressing cancer through early detection and prevention<\/i><\/p>\n<p class=\"bwalignc\"><i>Pearsanta plans further validation and regulatory submissions to support commercialization within its Richmond, Virginia CLIA\/CAP-certified monitoring center and laboratories<\/i><\/p>\n<p>MOUNTAIN VIEW, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAditxt, Inc. (NASDAQ: ADTX) (&#8220;Aditxt&#8221; or the &#8220;Company&#8221;), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. (&#8220;Pearsanta&#8221;), has acquired key patents related to adductomics-based DNA damage detection, which it believes will further strengthen its position in the cancer prevention-focused diagnostic industry.\n<\/p>\n<p>\nPearsanta acquired the patents in exchange for the issuance of Pearsanta Convertible Preferred Stock in a transaction valued at approximately $1 million. Over the next two to three years, Pearsanta will seek to advance clinical validation, regulatory submissions, and commercialization efforts to integrate this technology into its diagnostic portfolio.\n<\/p>\n<p>\nThe acquisition aligns with Pearsanta\u2019s mission to advance early cancer detection and prevention that is globally accessible. Mitomic<sup>\u00ae<\/sup> Technology, Pearsanta\u2019s proprietary platform, uses mitochondrial DNA biomarkers designed for non-invasive cancer detection. With the addition of adductomics-based DNA damage analysis, Pearsanta is expanding its capabilities to assess carcinogen exposure and genomic instability before permanent mutations occur, reinforcing its commitment to proactive cancer risk assessment.\n<\/p>\n<p><b>Enhancing Early Cancer Detection with Adductomics<\/b><\/p>\n<p>\nThe acquired patents cover proprietary advancements in DNA adduct detection and analysis, providing the capability to assess genomic instability caused by environmental toxins and metabolic byproducts. DNA adducts\u2014chemical modifications to DNA nucleotides caused by carcinogens\u2014are among the earliest detectable indicators of cancer risk.\n<\/p>\n<p>\nPearsanta intends to develop this platform into a comprehensive, panoramic assessment tool for DNA adducts, utilizing urine, blood or solid tissue samples to provide actionable insights into DNA damage before mutations occur. This approach has the potential to identify environmental or biological factors contributing to cancer risk, offering earlier intervention strategies for individuals at elevated risk.\n<\/p>\n<p><b>Advancing Toward Commercialization<\/b><\/p>\n<p>\nPearsanta is advancing a strategic development plan to bring adductomics-based diagnostics to market, focusing on:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nClinical validation to confirm the technology\u2019s effectiveness in assessing cancer risk.\n<\/li>\n<li>\nRegulatory submissions to support integration into Laboratory Developed Tests (LDTs) and future FDA pathways.\n<\/li>\n<li>\nScalability within CLIA\/CAP-certified laboratories, seeking to ensure clinical access and, ultimately, commercial adoption.\n<\/li>\n<\/ul>\n<p>\nOver the next two to three years, Pearsanta aims to incorporate adductomics-based screening into its expanding portfolio of precision oncology solutions, reinforcing its commitment to shifting cancer diagnostics from late-stage detection to proactive prevention.\n<\/p>\n<p><b>Pearsanta\u2019s Role in the Future of Cancer Prevention<\/b><\/p>\n<p>\nCurrent cancer diagnostics predominantly detect tumors after they have developed, leaving patients with limited treatment options that are often costly and less effective. Pearsanta\u2019s approach, strengthened by the acquisition of adductomics technology, represents a new frontier in cancer prevention, potentially facilitating identification of DNA damage at its earliest molecular stages\u2014before irreversible mutations occur.\n<\/p>\n<p>\n\u201cWe envision a world where cancer risk can be assessed before symptoms appear, giving patients and physicians the opportunity to intervene when it matters most,\u201d said Chris Mitton, President of Pearsanta. \u201cWe believe that Pearsanta is uniquely positioned to shift cancer care from reactive treatment to proactive prevention. This advancement has the potential to redefine cancer care by enabling earlier risk assessment, allowing individuals to adjust lifestyle factors, reduce exposure to carcinogens and adopt personalized prevention strategies. In underserved regions, where access to oncology treatments remains limited, we believe that adductomics-based screening could provide a cost-effective tool for early cancer risk assessment, empowering preventive measures when they are most effective.\u201d\n<\/p>\n<p>\nAdditionally, by detecting DNA damage before disease progression, this technology has the potential to lower the overall economic burden of cancer, reducing the reliance on late-stage treatments and hospitalizations.\n<\/p>\n<p>\n\u201cPearsanta\u2019s acquisition reflects Aditxt\u2019s commitment to driving innovation with the potential of addressing some of the most pressing health challenges such as cancer,\u201d said Amro Albanna, Co-Founder, Chairman, and CEO of Aditxt. \u201cWe believe that this technology has the potential to redefine how we assess and mitigate cancer risk, which could reshape the future of early detection and prevention of cancer.\u201d\n<\/p>\n<p><b>About Pearsanta<\/b><\/p>\n<p>\nPearsanta is at the forefront of precision health, focusing on early cancer detection through advanced diagnostic technologies. Its proprietary Mitomic Technology Platform leverages the unique properties of mitochondrial DNA to detect cancer and other diseases with high accuracy via non-invasive, blood-based liquid biopsy tests. Pearsanta&#8217;s asset portfolio also includes a range of other innovative diagnostic technologies, all aimed at transforming early disease detection and monitoring, enabling more informed treatment decisions and ultimately improving patient outcomes. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.pearsanta.com%2F&amp;esheet=54227701&amp;newsitemid=20250324843574&amp;lan=en-US&amp;anchor=www.pearsanta.com.&amp;index=1&amp;md5=9269bb5088fa28f9193b194ae7ee127d\">www.pearsanta.com.<\/a><\/p>\n<p><b>About Aditxt<\/b><\/p>\n<p>\nAditxt, Inc.<sup>\u00ae<\/sup> is a social innovation platform dedicated to accelerating promising health innovations. Aditxt\u2019s ecosystem of research institutions, industry partners, and shareholders collaboratively drives its mission to &#8220;Make Promising Innovations Possible Together.&#8221; The innovation platform is the cornerstone of Aditxt\u2019s strategy, where multiple disciplines drive disruptive growth and address significant societal challenges. Aditxt operates a unique model that democratizes innovation, ensures every stakeholder\u2019s voice is heard and valued, and empowers collective progress.\n<\/p>\n<p>\nAditxt currently operates two programs focused on immune health and precision health. The Company plans to introduce two additional programs dedicated to public health and women\u2019s health. For these, Aditxt has entered into an Arrangement Agreement with Appili Therapeutics, Inc. (&#8220;Appili&#8221;) (TSX: APLI; OTCPink: APLIF), which focuses on infectious diseases, and a Merger Agreement with Evofem Biosciences, Inc. (&#8220;Evofem&#8221;) (OTCQB: EVFM). Each program will be designed to function autonomously while collectively advancing Aditxt\u2019s mission of discovering, developing and deploying innovative health solutions to tackle some of the most urgent health challenges. The closing of each of the transactions with Appili and Evofem is subject to several conditions, including but not limited to approval of the transactions by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing. These obligations include cash payments of approximately $17 million for Appili and $17 million for Evofem, which includes approximately $15.2 million required to satisfy Evofem&#8217;s senior secured noteholder; should Aditxt fail to secure these funds, Evofem&#8217;s senior secured noteholder is expected to seek to prevent the closing of the merger with Evofem. On Dec. 23, 2024, Evofem announced the cancellation of its special stockholders meeting and the withdrawal of the merger proposal with Aditxt from consideration by the stockholders. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that either of the transactions will ultimately close.\n<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nCertain statements in this press release constitute &#8220;forward-looking statements&#8221; within the meaning of federal securities laws. Forward-looking statements include statements regarding the Company\u2019s intentions, beliefs, projections, outlook, analyses, or current expectations concerning, among other things, the Company\u2019s ongoing and planned product and business development; the Company\u2019s ability to finance and execute its strategic M&amp;A initiatives; the Company\u2019s ability to obtain the necessary funding and partner to commence clinical trials; the Company\u2019s intellectual property position; the Company\u2019s ability to develop commercial functions; expectations regarding product launch and revenue; the Company\u2019s results of operations, cash needs, spending, financial condition, liquidity, prospects, growth, and strategies; the Company\u2019s ability to raise additional capital; expected usage of the Company\u2019s ELOC and ATM facilities; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as market and other conditions and those risks more fully discussed in the section titled &#8220;Risk Factors&#8221; in Aditxt\u2019s most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company\u2019s other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250324843574r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20250324843574\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20250324843574\/en\/<\/a><\/span><\/p>\n<p><b>Aditxt, Inc.<br \/>\n<\/b><br \/>Corporate Communications<br \/>\n<br \/>Jeff Ramson, PCG Advisory, Inc.<br \/>\n<br \/>T: 646-863-6893\n<\/p>\n<p><b>KEYWORDS:<\/b> United States North America California<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Oncology Health Genetics Health Technology Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk Acquisition is key to Pearsanta\u2019s mission of addressing cancer through early detection and prevention Pearsanta plans further validation and regulatory submissions to support commercialization within its Richmond, Virginia CLIA\/CAP-certified monitoring center and laboratories MOUNTAIN VIEW, Calif.&#8211;(BUSINESS WIRE)&#8211; Aditxt, Inc. (NASDAQ: ADTX) (&#8220;Aditxt&#8221; or the &#8220;Company&#8221;), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. (&#8220;Pearsanta&#8221;), has acquired key patents related to adductomics-based DNA damage detection, which it believes will further strengthen its position in the cancer prevention-focused diagnostic industry. Pearsanta acquired the patents in exchange &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-828906","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk Acquisition is key to Pearsanta\u2019s mission of addressing cancer through early detection and prevention Pearsanta plans further validation and regulatory submissions to support commercialization within its Richmond, Virginia CLIA\/CAP-certified monitoring center and laboratories MOUNTAIN VIEW, Calif.&#8211;(BUSINESS WIRE)&#8211; Aditxt, Inc. (NASDAQ: ADTX) (&#8220;Aditxt&#8221; or the &#8220;Company&#8221;), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. (&#8220;Pearsanta&#8221;), has acquired key patents related to adductomics-based DNA damage detection, which it believes will further strengthen its position in the cancer prevention-focused diagnostic industry. Pearsanta acquired the patents in exchange &hellip; Continue reading &quot;Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-24T12:18:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250324843574r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk\",\"datePublished\":\"2025-03-24T12:18:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\\\/\"},\"wordCount\":1433,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250324843574r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\\\/\",\"name\":\"Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250324843574r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2025-03-24T12:18:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250324843574r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20250324843574r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\/","og_locale":"en_US","og_type":"article","og_title":"Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk - Market Newsdesk","og_description":"Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk Acquisition is key to Pearsanta\u2019s mission of addressing cancer through early detection and prevention Pearsanta plans further validation and regulatory submissions to support commercialization within its Richmond, Virginia CLIA\/CAP-certified monitoring center and laboratories MOUNTAIN VIEW, Calif.&#8211;(BUSINESS WIRE)&#8211; Aditxt, Inc. (NASDAQ: ADTX) (&#8220;Aditxt&#8221; or the &#8220;Company&#8221;), a social innovation platform accelerating promising health innovations, today announced that its subsidiary, Pearsanta, Inc. (&#8220;Pearsanta&#8221;), has acquired key patents related to adductomics-based DNA damage detection, which it believes will further strengthen its position in the cancer prevention-focused diagnostic industry. Pearsanta acquired the patents in exchange &hellip; Continue reading \"Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-24T12:18:07+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250324843574r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk","datePublished":"2025-03-24T12:18:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\/"},"wordCount":1433,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250324843574r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\/","name":"Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250324843574r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2025-03-24T12:18:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250324843574r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20250324843574r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aditxt-subsidiary-pearsanta-completes-the-acquisition-of-proprietary-adductomics-technology-to-develop-and-advance-the-platform-toward-clinical-and-commercial-applications-for-monitoring-early-signs-o\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aditxt Subsidiary Pearsanta Completes the Acquisition of Proprietary Adductomics Technology to Develop and Advance the Platform Toward Clinical and Commercial Applications for Monitoring Early Signs of Increased Cancer Risk"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/828906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=828906"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/828906\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=828906"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=828906"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=828906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}